Drug Trial Radar · NCT06320431
ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
4,000
Planned (sponsor's estimate)
Start
Sep 26, 2024
Primary completion
Sep 30, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- University of CalgaryAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The George Institute for Global Health, Australia
- First posted
- Mar 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design. Up to 4,000 patients with presumed acute ischemic stroke (AIS) will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment. This domain aim is to efficiently, reliably, and simultaneously, determine the comparative effectiveness of intravenous thrombolysis (IVT) using standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) in all patients who present to hospital with acute ischemic stroke and are considered for intravenous thrombolysis. In addition, this domain also seeks to study standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) vs. no TNK upfront with rescue IA TNK if necessary (in those eligible for emergency EVT) and no TNK upfront in those who have taken DOACs during the preceding 48 hours. This domain therefore seeks to generate more robust randomized evidence to guide clinicians in their decisions over the balance of risks and treatment with intravenous thrombolysis with tenecteplase wherever such evidence is currently insufficient. This domain will currently evaluate four research questions in relation to the use of IVT with tenecteplase: 1. In patients with recent (48 hours) intake of a standard-dose direct oral anticoagulant (DOAC), how should IVT be used? - Use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg) or not at all. 2. In patients planned to be treated with endovascular thrombectomy, how should tenecteplase be used? -Treat with IV tenecteplase (standard- or low-dose) or not at all. 3. In any patient receiving IVT, what is the optimal dose of tenecteplase? - use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg). 4. To what extent is the treatment effect of standard- vs. low-dose tenecteplase modified by key patient characteristics, such as diabetes, prior antiplatelet therapy, renal failure, or frailty, old age or having a heavy burden of cerebral small vessel disease on brain imaging.
Conditions
- Acute Ischemic Stroke AIS
- Stroke Acute
- Stroke, Acute, Stroke Ischemic
Interventions
TenecteplaseDrug
Thrombolytic
Primary outcomes
What the sponsor says the trial is designed to measure.
- A reduction of functional dependence analyzed across the whole distribution of outcomes assessed on the modified Rankin Scale (mRS),Time frame: From enrollment to the Day 90 assessment - Day 90 outcomes are assessed in a blinded manner
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
The George Institute for Global Health
Sydney, Barangaroo, Australia · Not yet recruiting
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia · Recruiting
Monash University (Box Hill)
Melbourne, Victoria, Australia · Recruiting
University of Alberta
Edmonton, A, Canada · Recruiting
University of Calgary
Calgary, Alberta, Canada · Recruiting
Medicine Hat Regional Hospital
Medicine Hat, Alberta, Canada · Not yet recruiting
Red Deer Regional Hospital
Red Deer, Alberta, Canada · Not yet recruiting
Kelowna Regional Hospital
Kelowna, British Columbia, Canada · Not yet recruiting
Royal Columbian Hospital
New Westminster, British Columbia, Canada · Not yet recruiting
University of British Columbia
Vancouver, British Columbia, Canada · Recruiting
Brandon Regional Hospital
Brandon, Manitoba, Canada · Not yet recruiting
University of Manitoba - Winnipeg Health Science Centre
Winnipeg, Manitoba, Canada · Recruiting
Queen Elizabeth II Health Science Center (Halifax)
Halifax, Nova Scotia, Canada · Not yet recruiting
Health Sciences North Horizon Sante-Nord
Greater Sudbury, Ontario, Canada · Recruiting
McMaster University Hamilton Health Sciences Centre
Hamilton, Ontario, Canada · Recruiting
Kingston General Hospital
Kingston, Ontario, Canada · Not yet recruiting
Lawson Health Research Institute- London
London, Ontario, Canada · Not yet recruiting
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada · Recruiting
St. Michael's Hospital
Toronto, Ontario, Canada · Recruiting
Sunnybrook Health Science Centre
Toronto, Ontario, Canada · Recruiting
Queen Elizabeth Hospital (PEI)
Charlottetown, Prince Edward Island, Canada · Recruiting
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada · Not yet recruiting
CIUSSS de l'Estrie - CHUS Fleurimont Hôpital (Sherbrooke)
Sherbrooke, Quebec, Canada · Not yet recruiting
Royal University Hospital
Saskatoon, Saskatchewan, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.